Elezanumab
Pre-clinicalActive 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Spinal Cord Injury (SCI)
Conditions
Acute Spinal Cord Injury (SCI)
Trial Timeline
— → —
NCT ID
NCT04278235About Elezanumab
Elezanumab is a pre-clinical stage product being developed by AbbVie for Acute Spinal Cord Injury (SCI). The current trial status is active. This product is registered under clinical trial identifier NCT04278235. Target conditions include Acute Spinal Cord Injury (SCI).
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04278235 | Pre-clinical | Active |
Competing Products
20 competing products in Acute Spinal Cord Injury (SCI)